Placenta praevia - does it really affect intrauterine fetal growth?


Journal

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
ISSN: 1476-4954
Titre abrégé: J Matern Fetal Neonatal Med
Pays: England
ID NLM: 101136916

Informations de publication

Date de publication:
Oct 2022
Historique:
pubmed: 14 11 2020
medline: 30 8 2022
entrez: 13 11 2020
Statut: ppublish

Résumé

Placenta praevia affects about 0.5% of pregnancies and due to constant increase in operative deliveries may become an important, clinical challenge throughout the next decades. Location of the placental plate within lower uterine segment is associated with increased risk of adverse perinatal outcomes. There were several reports pointing increased risk of small-for-gestational-age (SGA)/fetal growth restriction (FGR) in patients affected with abnormal location of the placenta. On the other hand, some studies ended up with opposite conclusions. Due to ambiguous results we have undertaken a case-control study to investigate intrauterine growth among this group. We ran a pilot study to precisely define maternal, obstetrical and neonatal characteristics in order to avoid cofounders. Our study incorporated 56 patients in singleton pregnancies affected with placenta praevia and 124 patients in the control group (between 35 and 37 weeks of gestation). Nonetheless, there were no statistical differences in the birthweight between the study and control group (2882.5 g vs. 2805 g, p = ns). Moreover, rates of the newborns with birthweight corresponding <10th percentile and >90th did not differ significantly. Even further analysis that included parity did not reveal any differences between both groups. Placenta praevia does not affect the intrauterine growth and shall not be considered as a risk factor for SGA/FGR. In patients affected with abnormal location of the placenta additional scans for fetal well-being assessment are not indicated.

Identifiants

pubmed: 33183106
doi: 10.1080/14767058.2020.1843152
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3898-3902

Auteurs

Michał Lipa (M)

1st Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland.

Ksawery Goławski (K)

1st Department of Obstetrics and Gynecology, Students' Scientific Group, Medical University of Warsaw, Warsaw, Poland.

Przemysław Kosiński (P)

1st Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland.

Mirosław Wielgoś (M)

1st Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland.

Dorota Bomba-Opoń (D)

1st Department of Obstetrics and Gynecology, Medical University of Warsaw, Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH